GlassScriptPhysician profile
Rashad Ansari
NPI 1063594372
$17,239.28
in general payments reported to CMS, 2019-2025
33 companies · $2,244 in 2025
The $2,244 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,179 · 2020: $1,935 · 2021: $2,427 · 2022: $2,452 · 2023: $3,003 · 2024: $2,999 · 2025: $2,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,246.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,318.33 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $2,620.07 | 2019-2025 | Rinvoq, Humira, Skyrizi |
| Janssen Biotech, INC. | $2,385.89 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $1,308.95 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $1,188.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,106.49 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $860.33 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $781.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $714.30 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $491.14 | 2019-2025 | Sotyktu, Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $485.01 | 2019-2024 | Ofev, Cyltezo |
| Genentech USA, INC. | $291.96 | 2019-2025 | Actemra |
| Actelion Pharmaceuticals US, INC. | $238.25 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Aurinia Pharma U.S., INC. | $220.26 | 2021-2025 | Lupkynis |
| Celgene Corporation | $184.30 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $164.76 | 2020-2023 | |
| Genzyme Corporation | $145.78 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $138.37 | 2024 | Tremfya |
| Sanofi-Aventis U.S. LLC | $93.17 | 2019-2020 | |
| Fidia Pharma USA INC. | $85.97 | 2019-2020 | |
| Depuy Synthes Sales INC. | $71.56 | 2023-2024 | Orthovisc |
| Biocryst US Sales Co., LLC | $68.89 | 2023-2024 | Orladeyo |
| Sandoz INC. | $62.07 | 2025 | Hyrimoz |
| Celltrion USA INC. | $39.03 | 2024-2025 | Vegzelma |
| Kyowa Kirin, INC. | $26.85 | 2025 | |
| Biocon Biologics INC | $23.01 | 2023 | Hulio |
| Fresenius Kabi USA, LLC | $20.64 | 2024 | Idacio |
| Collegium Pharmaceutical, INC. | $19.94 | 2021 | |
| Avanos Medical | $19.10 | 2023 | Trivisc Sodium Hyaluronate |
| Horizon Therapeutics Plc | $17.13 | 2023 | Krystexxa |
| Sobi, INC | $16.35 | 2019 | |
| Tonix Medicines, INC. | $15.88 | 2025 | Tonmya |
| Kiniksa Pharmaceuticals, LTD. | $15.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.